Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC

• Autores principales: Pingyu Chen (Autor), Xintian Wang (Autor), Shengwen Zhu (Autor), Hongchao Li (Autor), Mingjun Rui (Autor), Yingcheng Wang (Autor), Haikui Sun (Autor), Aixia Ma (Autor)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Background and objectiveSintilimab has superior efficacy and safety in patients with advanced or metastatic squamous non-small cell lung cancer (NSCLC), but its cost-effectiveness in China is unclear. This study is to evaluate the cost-effectiveness of sintilimab plus chemotherapy vs. pembrolizumab...